Copper Therapy Enhances Cognitive Function and Learning

Monash University researchers found that the copper compound Cu(ATSM) increases brain clearance pumps by 24.1%, reducing toxic amyloid-beta proteins by 42%. According to a study published in ACS Chemical Neuroscience, this treatment repairs the blood-brain barrier and improves spatial learning by nearly 44% in Alzheimer’s disease models.

How does Cu(ATSM) repair the brain’s waste-clearing system?

Alzheimer’s disease is largely driven by the accumulation of amyloid-beta, a toxic protein that builds up in the brain. In a healthy brain, P-glycoprotein (P-gp) pumps act as a waste-clearing mechanism, flushing these proteins across the blood-brain barrier and into the bloodstream.

In Alzheimer’s patients, these P-gp pumps weaken. This failure “clogs the drain,” trapping toxic proteins inside the brain tissue. Dr. Jae Pyun, a researcher at the Monash Institute of Pharmaceutical Sciences (MIPS), found that the Cu(ATSM) compound successfully engages the brain’s blood vessels to restore this process.

By increasing the abundance of these clearance pumps, the drug allows the brain to expel the trapped waste. Dr. Pyun noted that this repair of the blood-brain barrier is directly linked to the reduction of toxic proteins and improved cognitive function.

What specific improvements did the researchers observe?

The laboratory experiments, conducted over a 56-day period, produced measurable biological and behavioral changes. The study’s data shows a direct correlation between pump restoration and cognitive recovery:

• Pump Abundance: P-gp clearance pumps increased by 24.1%.
• Protein Reduction: Toxic amyloid-beta levels dropped by 42%.
• Cognitive Function: Spatial learning improved by nearly 44%.

While the primary mechanism involves the blood-brain barrier, researchers suspect a secondary benefit. They are currently investigating whether the copper treatment empowers microglia—the brain’s own immune cells—to consume and degrade toxic plaques.

Comparing Biological Impacts

The study highlights a significant gap between the physical repair of the barrier and the resulting cognitive benefit. While the P-gp pump abundance increased by roughly one-quarter (24.1%), the resulting reduction in toxic protein was nearly double that rate (42%). This suggests that even modest repairs to the neurovascular system can have outsized effects on protein clearance.

When could this treatment reach human patients?

The transition from laboratory models to human clinical trials may be faster than traditional Alzheimer’s drugs. Professor Joseph Nicolazzo, Director of the Centre for Drug Candidate Optimisation at MIPS, stated that Cu(ATSM) has already undergone safety evaluations for other neurological conditions.

Because the compound possesses anti-inflammatory and neuroprotective properties, it is already progressing through clinical testing for Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). Professor Nicolazzo noted that these existing safety profiles provide a strong rationale for testing the drug in patients with early symptomatic Alzheimer’s disease.

How does this approach differ from existing Alzheimer’s therapies?

Most current Alzheimer’s research focuses on directly attacking amyloid-beta plaques. This new research shifts the focus toward “neurovascular dysfunction”—the failure of the brain’s plumbing system. Instead of just cleaning up the mess, Cu(ATSM) aims to fix the mechanism that prevents the mess from accumulating in the first place.

Future studies will attempt to map the exact biological routes these proteins take once they exit the brain. Understanding these precise clearance mechanisms is essential for developing biometal therapies that combat both memory loss and blood vessel dysfunction.